Table 3.
Clinical studies utilizing l-carnitine (CARN) (or acetyl-CARN (ALC)) aimed at compensating OS/MDF-related pathogenetic mechanisms.
| Diseases/Conditions | No. Studies (Controlled Studies) | No. Treated Patients | Success Ratio | References |
|---|---|---|---|---|
| Kidney diseases | 18 (16) | 427 | 0.58 | [184,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220] |
| Type 1 and Type 2 Diabetes | 13 (9) | 1894 | 1.00 | [221,222,223,224,225,226,227,228,229,230,231,232,233] |
| Heart and vessel diseases | 9 (6) | 359 | 1.00 | [78,114,234,235,236,237,238,239,240] |
| Liver diseases | 6 (2) | 275 | 1.00 | [241,242,243,244,245,246] |
| Neurological diseases | 9 (9) | 384 | 1.00 | [68,247,248,249,250,251,252,253,254] |
| Malignancies | 7 (6) | 699 | 0.70 | [255,256,257,258,259,260,261] |
| Genetic diseases | 6 (4) | 202 | 1.00 | [262,263,264,265,266,267] |
| HIV | 4 (1) | 93 | 1.00 | [97,268,269,270] |
| Other diseases § | 2 (2) | 99 | 1.00 | [271,272] |
| Total | 74 | 4432 |